ILC2s in cancer: good, bad, or stay tuned?

IF 12.8 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Trends in molecular medicine Pub Date : 2025-07-11 DOI:10.1016/j.molmed.2025.06.010

Sara Asif, Megan Kinzel, Barbara Vanderhyden, Nicolas Jacquelot, Michele Ardolino

引用次数: 0

Abstract

Group 2 innate lymphoid cells (ILC2s) are emerging players in tumor immunity. ILC2 heterogeneity confers tissue-specific outcomes, with sometimes opposing effects on the prognosis and progression of various cancers. The role of ILC2s in breast and ovarian cancer is an active area of investigation, with research aimed at leveraging these cells to enhance immunotherapy.

查看原文本刊更多论文

ILC2s在癌症中的作用：好，坏，还是继续关注？

2组先天淋巴样细胞（ILC2s）是肿瘤免疫中的新兴角色。ILC2异质性赋予组织特异性结果，有时对各种癌症的预后和进展有相反的影响。ILC2s在乳腺癌和卵巢癌中的作用是一个活跃的研究领域，研究旨在利用这些细胞来增强免疫治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in molecular medicine 医学-生化与分子生物学

CiteScore

24.60

自引率

0.00%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Trends in Molecular Medicine (TMM) aims to offer concise and contextualized perspectives on the latest research advancing biomedical science toward better diagnosis, treatment, and prevention of human diseases. It focuses on research at the intersection of basic biology and clinical research, covering new concepts in human biology and pathology with clear implications for diagnostics and therapy. TMM reviews bridge the gap between bench and bedside, discussing research from preclinical studies to patient-enrolled trials. The major themes include disease mechanisms, tools and technologies, diagnostics, and therapeutics, with a preference for articles relevant to multiple themes. TMM serves as a platform for discussion, pushing traditional boundaries and fostering collaboration between scientists and clinicians. The journal seeks to publish provocative and authoritative articles that are also accessible to a broad audience, inspiring new directions in molecular medicine to enhance human health.